None
Quote | Gritstone Oncology Inc. (NASDAQ:GRTS)
Last: | $0.8134 |
---|---|
Change Percent: | 0.81% |
Open: | $0.7583 |
Close: | $0.8134 |
High: | $0.8356 |
Low: | $0.7583 |
Volume: | 1,106,265 |
Last Trade Date Time: | 04/26/2024 03:00:00 am |
News | Gritstone Oncology Inc. (NASDAQ:GRTS)
-- Paper details vaccine design optimization process of Gritstone’s “off-the-shelf” or shared neoantigen vaccine platform, SLATE -- -- Discovery of a novel immunodominance hierarchy of tumor neoantigens (including KRAS) enabled the development of a more potent, KRAS...
-- State-of-the-art neoantigen prediction platform (EDGE ™ ) now predicts HLA Class I presentation of epitopes with >80% accuracy -- -- Newly developed EDGE-II model achieves superior predictive performance of HLA Class II presentation and CD4+ immunogenicity over publicly...
Message Board Posts | Gritstone Oncology Inc. (NASDAQ:GRTS)
Subject | By | Source | When |
---|---|---|---|
AACR PR https://www.globenewswire.com/news-release/2023/04/17/2647754/0/en/Grits | jondoeuk | investorshub | 04/17/2023 8:03:02 PM |
Nice...$$$$!!!???????? | Little Run | investorshub | 01/07/2023 12:19:22 AM |
Nice...$$$$!!!???????? | Little Run | investorshub | 01/07/2023 12:19:21 AM |
Holy Fuck...Still just me! | Little Run | investorshub | 12/21/2022 2:25:03 AM |
znewcar1: $GRTS 26% v6,19M C3.92 f83,4M H4.05 ML2.49 | znewcar1 | investorshangout | 12/15/2022 12:55:46 AM |
News, Short Squeeze, Breakout and More Instantly...
Gritstone Oncology Inc. Company Name:
GRTS Stock Symbol:
NASDAQ Market:
Gritstone Oncology Inc. Website:
-- Paper details vaccine design optimization process of Gritstone’s “off-the-shelf” or shared neoantigen vaccine platform, SLATE -- -- Discovery of a novel immunodominance hierarchy of tumor neoantigens (including KRAS) enabled the development of a more potent, KRAS...
-- State-of-the-art neoantigen prediction platform (EDGE ™ ) now predicts HLA Class I presentation of epitopes with >80% accuracy -- -- Newly developed EDGE-II model achieves superior predictive performance of HLA Class II presentation and CD4+ immunogenicity over publicly...
NEW YORK, NY / ACCESSWIRE / April 4, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Gritstone bio, Inc. ("Gritstone" or "the Company") (NASDAQ:GRTS). Investors who purchased Gritstone securities are encouraged to obtain additional infor...